Previous Close | 0.2300 |
Open | 0.2400 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.2400 - 0.2400 |
52 Week Range | 0.1100 - 0.4107 |
Volume | |
Avg. Volume | 22,160 |
Market Cap | 12.88M |
Beta (5Y Monthly) | 1.80 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results and operational highlights for the fiscal quarter ended February 29, 2024. The Company generated revenues of $686,205 during this period, driven by strong sales performance of its flagship product, DirectInject-LC™. O
A new approach isolates lithium and valuable transition metals from battery recycling feeds Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company") is leading a developer of advanced technologies and services for the global pharmaceutical and chemical industries. The Company focuses on process innovation, particularly for the production of medicinal compounds and battery materials. Telescope announces
Telescope pairs its DirectInject-LC(TM) technology with Shimadzu's chemical analysis instrumentation Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of enabling technologies for the global pharmaceutical and chemical industries, announces that it is engaged in a technology integration partnership with Shimadzu Scientific Instruments, Inc. ("Shimadzu"). Shimadzu is a global leade